UroGen Pharma Ltd. (NASDAQ:URGN) Given Average Rating of “Buy” by Brokerages

UroGen Pharma Ltd. (NASDAQ:URGN) has received an average rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $43.70.

URGN has been the topic of several research analyst reports. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a research report on Friday, December 6th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a report on Tuesday, October 15th. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. Finally, EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th.

UroGen Pharma Price Performance

Shares of NASDAQ:URGN opened at $11.01 on Tuesday. UroGen Pharma has a 52 week low of $10.26 and a 52 week high of $20.70. The company has a 50-day moving average price of $11.73 and a 200 day moving average price of $13.51. The company has a market cap of $258.23 million, a P/E ratio of -3.50 and a beta of 1.09. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same period in the prior year, the business earned ($0.68) earnings per share. Research analysts predict that UroGen Pharma will post -3.1 earnings per share for the current year.

Institutional Trading of UroGen Pharma

Several institutional investors and hedge funds have recently modified their holdings of URGN. Marshall Wace LLP acquired a new position in shares of UroGen Pharma during the 2nd quarter worth approximately $719,000. Millennium Management LLC increased its position in UroGen Pharma by 2,672.0% during the second quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock worth $19,480,000 after buying an additional 1,119,019 shares in the last quarter. Point72 Asset Management L.P. increased its position in UroGen Pharma by 120.3% during the second quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock worth $41,099,000 after buying an additional 1,337,257 shares in the last quarter. Barclays PLC raised its holdings in shares of UroGen Pharma by 409.3% in the third quarter. Barclays PLC now owns 59,778 shares of the company’s stock worth $759,000 after acquiring an additional 48,040 shares during the last quarter. Finally, Wesbanco Bank Inc. purchased a new stake in shares of UroGen Pharma in the third quarter valued at $945,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.